NUS researchers use magnetic pulses to reprogram immune cells against breast cancer

Researchers from the National University of Singapore have demonstrated a non-invasive approach using pulsed electromagn...

September 15, 2026 | Tuesday | News
Kelun-Biotech reports Phase III benefit for trastuzumab botidotin in HER2-positive breast cancer

Sichuan Kelun-Biotech Biopharmaceutical has reported published Phase III results for trastuzumab botidotin in patients w...

September 15, 2026 | Tuesday | News
CMS begins clinical rollout of Silevimig, first bispecific antibody for rabies passive immunisation

China Medical System Holdings has announced that initial prescriptions for Silevimig Injection have been issued at multi...

September 10, 2026 | Thursday | News
Ascletis starts US Phase I trial of oral amylin agonist ASC36 for obesity

Ascletis Pharma has initiated a US Phase I clinical study of ASC36 oral tablets, an investigational amylin receptor pept...

September 9, 2026 | Wednesday | News
Everest Medicines wins China approval for CARDAMYST in acute PSVT

Everest Medicines has received approval from China’s National Medical Products Administration for CARDAMYST, or et...

September 7, 2026 | Monday | News
Everest Medicines’ LEROCHOL BLA accepted in China for hypercholesterolemia

Everest Medicines has announced that China’s National Medical Products Administration has accepted the Biologics L...

September 7, 2026 | Monday | News
Japan's Ono Pharma enters into drug discovery partnership with Aitia for neurological diseases treatment

Japan-based Ono Pharmaceutical has entered into a drug discovery partnership agreement with US-based Aitia, Inc. Under t...

September 4, 2026 | Friday | News
Ascletis doses first participant in global Phase III trial of oral GLP-1 candidate ASC30

Ascletis Pharma has dosed the first participant in its global Phase III clinical programme evaluating ASC30, an investig...

September 2, 2026 | Wednesday | News
Singapore becomes first ASEAN market to subsidise vutrisiran for transthyretin amyloidosis

Singapore has become the first ASEAN country to provide government subsidies for eligible patients receiving vutrisiran ...

September 2, 2026 | Wednesday | News
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110

Taiwan-based Formosa Pharmaceuticals has submitted a Clinical Trial Application to European regulators for a pivotal stu...

August 31, 2026 | Monday | News
DualityBio and Genentech partner on next-generation ADCs in deal worth over $1 billion

Shanghai-based DualityBio has entered a global collaboration and licensing agreement with Genentech to develop next-gene...

August 31, 2026 | Monday | News
Fosun Pharma strengthens innovation pipeline as Henlius and global drug portfolio expand

Fosun Pharma continued to strengthen its innovation-led growth strategy in the first half of 2026, supported by increasi...

August 31, 2026 | Monday | News
Alebund advances renal pipeline as AP301 enters China regulatory review

Alebund Pharmaceuticals has reported progress across its renal disease portfolio, including completion of enrolment in a...

August 28, 2026 | Friday | News
Antengene receives Australian clearance for Phase I ATG-201 autoimmune disease trial

Antengene has received approval in Australia to initiate a Phase I clinical study of ATG-201, its investigational CD19/C...

August 28, 2026 | Friday | News
Shimadzu invests in OptQC to advance next-generation R&D infrastructure for drug discovery

Japan-based Shimadzu Corporation has invested in OptQC Inc., a startup originating from The University of Tokyo, through...

August 26, 2026 | Wednesday | News
Deep Origin explores combining AI and physics to improve virtual screening in drug discovery

Artificial intelligence is increasingly being applied across early-stage drug discovery, but translating computational p...

August 25, 2026 | Tuesday | Opinion
ABio on developing LANFA as a next-generation alternative to PEG in drug delivery

Drug delivery technologies have become increasingly important as pharmaceutical developers work with complex molecules, ...

August 25, 2026 | Tuesday | Opinion
Akeso receives China clinical trial clearance for B7-H3 ADC AK157D1

Akeso has received clinical trial clearance from China’s Center for Drug Evaluation for AK157D1, a next-generation...

August 24, 2026 | Monday | News
CureGene doses first participant in Phase I trial of liver-targeting CG-0416

CureGene has dosed the first participant in an Australian Phase I clinical trial of CG-0416, an investigational oral liv...

August 24, 2026 | Monday | News
Indian societies issue first joint consensus on personalised obesity management

The Obesity and Metabolic Surgery Society of India and the Endocrine Society of India have issued their first joint cons...

August 21, 2026 | Friday | News
Brown University Health and Arcamyra to launch Phase I trial of ACM-CpG in peritoneal carcinomatosis

Brown University Health and Arcamyra Therapeutics are preparing to launch a Phase I clinical trial of ACM-CpG in patient...

August 20, 2026 | Thursday | News
Apodex launches TRACES benchmark to evaluate AI for scientific discovery

Apodex has launched TRACES, a benchmark designed to evaluate how artificial intelligence systems perform on open-ended s...

August 18, 2026 | Tuesday | News
Dx&Vx expands KRNA nucleic acid stabilisation programme into Latin America

South Korean biopharmaceutical company Dx&Vx has signed two material transfer agreements in Latin America for its KR...

August 13, 2026 | Thursday | News
Ascletis begins two US Phase I studies of once-monthly obesity candidates

Ascletis Pharma has initiated two Phase I studies in the United States evaluating investigational once-monthly injectabl...

August 13, 2026 | Thursday | News
Tumour-like tissue environments offer new target for HIV cure research

Scientists at Northwestern University have found that tissue environments surrounding persistent viral reservoirs share ...

August 6, 2026 | Thursday | News